Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage.

Michael R. Hoane, Jeremy L. Pierce, Nicholas A. Kaufman, Jason E. Beare

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalOxidative medicine and cellular longevity
Volume1
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Niacinamide
Brain
Recovery
Wounds and Injuries
Forelimb
Therapeutics
Vibrissae
Touch
Traumatic Brain Injury
Recovery of Function
Rats
Adhesives
Clinical Protocols
Brain Contusion
Testing

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Cell Biology

Cite this

Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage. / Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.; Beare, Jason E.

In: Oxidative medicine and cellular longevity, Vol. 1, No. 1, 01.01.2008, p. 46-53.

Research output: Contribution to journalArticle

@article{593272d1a39d4912b4689b36d1a77ff4,
title = "Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage.",
abstract = "Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.",
author = "Hoane, {Michael R.} and Pierce, {Jeremy L.} and Kaufman, {Nicholas A.} and Beare, {Jason E.}",
year = "2008",
month = "1",
day = "1",
doi = "10.4161/oxim.1.1.6694",
language = "English (US)",
volume = "1",
pages = "46--53",
journal = "Oxidative Medicine and Cellular Longevity",
issn = "1942-0900",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage.

AU - Hoane, Michael R.

AU - Pierce, Jeremy L.

AU - Kaufman, Nicholas A.

AU - Beare, Jason E.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.

AB - Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.

UR - http://www.scopus.com/inward/record.url?scp=70349716003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349716003&partnerID=8YFLogxK

U2 - 10.4161/oxim.1.1.6694

DO - 10.4161/oxim.1.1.6694

M3 - Article

C2 - 19794908

AN - SCOPUS:70349716003

VL - 1

SP - 46

EP - 53

JO - Oxidative Medicine and Cellular Longevity

JF - Oxidative Medicine and Cellular Longevity

SN - 1942-0900

IS - 1

ER -